Skip to content

Simultaneous and Real-Time Imaging of Mitochondrial and Lysosomal ATP with Inducible Excessive Mitophagy for Antitumor Therapy via a Multifunctional Fluorescent Probe

Sep 2026 · Analytical Chemistry · 0 citations · 47 references

Abstract

Mitophagy is essential for mitochondrial quality control and cellular homeostasis, while its aberrant hyperactivation has emerged as a promising strategy to selectively eliminate cancer cells. This process depends on the adenosine triphosphate (ATP) interplay between mitochondria and lysosomes, yet probes that simultaneously enable dual-organelle ATP imaging and mitophagy regulation are still lacking. Herein, we report MLA, a powerful fluorescent probe that integrates spectrally resolved ATP imaging in both organelles with inducible excessive mitophagy. Bearing pH-adapted fluorophores and a glutathione (GSH)-cleavable disulfide, MLA operates in two modes: at low doses, it serves as a biocompatible reporter to map ATP fluctuations under various perturbations; at high doses, it depletes mitochondrial GSH, thereby triggering a reactive oxygen species (ROS) burst that induces excessive mitophagy and cancer cell death. Mechanistically, it was discovered that this process consumes the transmembrane glycoprotein Mucin 1 (MUC1) whose degradation blocks autophagic flux, and thus leads to lethal accumulation of undegraded autophagosomes, markedly suppressing proliferation. In vivo, MLA enables specific imaging of intratumoral ATP and exhibits tumor-inhibitory capacity. Co-administration with the ATP synthase inhibitor oligomycin A (Omy A) further amplifies the tumor-suppressive effect, validating a simultaneous and drastic ATP/GSH dual-depletion strategy as a feasible combination therapy. MLA represents the first fluorescent probe to synergize dual-organelle ATP imaging with mitophagy regulation, offering a powerful tool for fundamental research and a new paradigm for the design of versatile fluorescent probes.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.